Danaher Corporation

Getting therapies to patients faster remains one of the hardest challenges in science. At #BioITWorld, two Danaher companies are helping address this challenge from complementary angles.   Genedata has launched Vico, an AI-native platform that streamlines data and supports better decision-making across Chemistry, Manufacturing, and Controls (CMC). These processes ensure a drug is safe, effective, and consistently manufactured. By bringing together data and AI, Vico helps teams improve decisions and move more efficiently through development. Novartis adopted the platform to move beyond document‑based processes, improving how teams make decisions and accelerating progress toward regulatory submission and clinical trials. This work was recognized with Bio‑IT World's Innovative Practices Award for Real‑World AI.   IDBS provides a connected platform from research through CMC that standardizes workflows and captures high-quality, context-rich data—driving efficiency, accelerating decision-making, and enabling data science initiatives.   Together, these efforts point to where biopharma is headed: progress depends on how well data can be connected and used across the workflow, and what becomes possible when it is.   Congratulations to Novartis, Genedata, and the teams behind this work!

Bioprocessing is being asked to do more than it was designed for. As pipelines expand and therapies become more specialized, the gap between scientific progress and manufacturing reality is getting harder to ignore. What once scaled predictably now has to flex across modalities, volumes, and levels of variability. That pressure shows up in timelines, cost, and ultimately patient access, and it’s starting to expose the limits of how these systems were originally built. In this video, Danaher and Cytiva leaders Christopher Riley, Beate Dr. Mueller-Tiemann, and Jose-Carlos Gutiérrez-Ramos talk about why this moment feels different, and what it will take to build systems that can keep pace with the science.

Progress in biologics, cell therapies, and gene therapies is accelerating. Manufacturing systems now face pressure that earlier generations of science never placed on them.   As therapies grow more complex, processes that work in the lab often strain at scale. When that happens, timelines stretch, costs rise, and patients wait.   This is where bioprocessing sits today. Not as a downstream function, but as the point where innovation either holds or breaks.   In a recent perspective, Christopher Riley looks at why closing the gap between discovery and delivery is no longer a single technical fix. It’s a system-level challenge that depends on how well the bioprocessing ecosystem works together.   If scientific progress is accelerating, what has to change to ensure it reaches patients with speed, consistency, and confidence?   🔗 Read the POV: https://lnkd.in/gRF9BxJm

Baby KJ was born with a rare, potentially fatal genetic disease with limited treatment options and significant uncertainty. In response, the world's first personalized CRISPR‑based therapy was designed, manufactured, and administered to him in record time.   That effort is why teams from Children's Hospital of Philadelphia, Penn Medicine, University of Pennsylvania Health System, Innovative Genomics Institute, and Danaher Corporation received the ASGCT Catalyst Award this week at #ASGCT2026.   The work moved forward because people across medicine, academia, and industry stayed aligned on one outcome: turning a one‑of‑a‑kind scientific idea into a treatment for a child who needed it now. Doing that required coordination across research, manufacturing, and clinical care, with no precedent and no margin for delay. Danaher Life Sciences businesses Aldevron and Integrated DNA Technologies manufactured key components of this highly complex, personalized gene editing therapy at speed, with Aldevron producing the final drug product.   Congratulations to the teams whose collaboration made this possible, and to the broader cell and gene therapy community advancing what can be delivered when expertise, scale, and urgency come together.

Advancing scientific understanding is central to how we help improve human health, especially in complex areas like immunology, where new knowledge can change what’s possible for patients. Recently, we were proud to partner with the International Union of Immunological Societies (IUIS) as principal global sponsor of the International Day of Immunology, spotlighting this year’s theme: Regulatory T Cells – Guardians of Immune Balance. Through a global flagship webinar, experts explored how Tregs maintain immune tolerance and how advances in our understanding of these cells are reshaping approaches to cancer, infection, and autoimmune disease. Moments like this reflect how we help translate scientific insight into scalable solutions, connecting discovery, development, and manufacturing to bring innovation closer to patients. We were honored to have Nicole Selenko-Gebauer MD MBA, Group VP and Chief Innovation Officer, join the closing panel alongside leaders from IUIS, EFIS, Nature, and Frontiers, highlighting the role of cross-sector collaboration in accelerating progress. Interested in the perspectives shaping the future of immunology? Watch the full conversation: https://loom.ly/q1XCaxA

There is a critical layer of modern medicine that most people never see, and its ability to keep pace increasingly determines whether scientific breakthroughs become therapies patients can actually access. As scientific discovery accelerates, this often-invisible layer of medicine has become one of the central constraints shaping modern healthcare. The opportunity for impact has never been greater, yet the gap between what can be discovered in the lab and what can be manufactured affordably, at scale, and with consistent quality has widened. Bioprocessing is the system behind biologic therapies, where living cells are transformed into treatments at the scale, quality, and consistency patients depend on, and where progress increasingly relies on trusted partners working across the ecosystem to turn scientific potential into real‑world impact. Christopher Riley, EVP of Danaher’s Biotechnology Group and CEO of Cytiva, shares why bioprocessing has quietly become one of the most important challenges and opportunities facing healthcare today, and how enabling science to move faster, with confidence, can help close the gap between discovery and delivery. 🔗 Read the POV: https://lnkd.in/gRF9BxJm

Over five weeks of CEO Kaizen, the same lessons showed up repeatedly across teams, businesses, and geographies.    Five lessons from gemba: 1, Leaders learn alongside their teams at gemba, where the work is done.  2. AI can accelerate our ability to apply insights and take action.  3. Bringing the right people together shortens the path from problem to impact.  4. Kaizen is about focusing on the critical few to deliver breakthrough results.  5. There is nothing more important than keeping an open mind. This is what makes the Danaher Business System work. Teams can move from insight to impact faster and solve complex problems together, at scale.    The progress at gemba was remarkable. Thank you to Danaher associates worldwide whose dedication to continuous improvement and sustainment is what turns kaizen into real results.    What lesson from gemba has most shaped how you lead or solve problems?   📸 From this week’s CEO Kaizen events at Aldevron, Cytiva, Abcam

What would it take to move personalized genetic medicine from isolated breakthroughs to standard care?    A new Nature Magazine perspective by Fyodor Urnov and Danaher’s Sadik Kassim outlines a practical pathway forward, including:    ✔️ Clear, predictable regulatory decision-making for personalized therapies  ✔️ Manufacturing systems built for speed, quality, and appropriate scale  ✔️ Data and evidence frameworks that evolve with the science  ✔️ Access and reimbursement models aligned to patient impact    Progress depends on designing these elements to work together, accelerating the path from idea to impact through a connected, global ecosystem.    Read more: https://lnkd.in/gmCM2Wzg

When people with different perspectives, experiences, and expertise are valued, teams ask better questions, challenge assumptions, and solve problems others can’t. That’s how ideas move faster from discovery to real‑world impact. Across our global ecosystem, Inclusion & Belonging strengthens the way we collaborate within teams, across operating companies, and alongside customers, so we can tackle complex challenges more quickly, creatively, and confidently. Scroll through to see how belonging fuels innovation at Danaher, and a few of the moments that brought it to life so far this year ➡️

Personalized medicine doesn’t just need better science. It needs systems that can move ideas into real-world impact faster, with certainty, at the speed patients deserve. In a new Nature Magazine perspective, Fyodor Urnov and Danaher’s Sadik Kassim make the case that aligning regulation, manufacturing, and access is now the real constraint in personalized genetic medicine and the opportunity to accelerate progress at scale. The path from scientific promise to real-world impact runs through a connected ecosystem. 🔗 Read more: https://lnkd.in/gmCM2Wzg